Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern

被引：4

作者：

Garg, Ravendra ^{[1
]}

Liu, Qiang ^{[1
,2
,3
]}

Van Kessel, Jill ^{[1
]}

Asavajaru, Akarin ^{[1
]}

Uhlemann, Eva-Maria ^{[1
]}

Joessel, Morgane ^{[4
]}

Hamonic, Glenn ^{[1
]}

Khatooni, Zahed ^{[1
]}

Kroeker, Andrea ^{[1
]}

Lew, Jocelyne ^{[1
]}

Scruten, Erin ^{[1
]}

Pennington, Paul ^{[1
]}

Deck, William ^{[1
]}

Prysliak, Tracy ^{[1
]}

Nickol, Michaela ^{[1
]}

Apel, Falko ^{[4
]}

Courant, Thomas ^{[4
]}

Kelvin, Alyson A. ^{[1
,5
]}

Van Kessel, Andrew ^{[1
]}

Collin, Nicolas ^{[4
]}

Gerdts, Volker ^{[1
,2
]}

Koster, Wolfgang ^{[1
,2
]}

Falzarano, Darryl ^{[1
,2
]}

Racine, Trina ^{[1
,3
]}

Banerjee, Arinjay ^{[1
,2
,6
,7
,8
]}

机构：

[1] Univ Saskatchewan, Vaccine & Infect Dis Org VIDO, Saskatoon, SK S7N 5E3, Canada

[2] Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK S7N 5B4, Canada

[3] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK S7N 2Z4, Canada

[4] Vaccine Formulat Inst VFI, Plan Les Ouates, Switzerland

[5] Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada

[6] Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada

[7] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada

[8] Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada

来源：

VACCINE | 2024年 / 42卷 / 20期

基金：

加拿大健康研究院; 加拿大创新基金会;

关键词：

ADJUVANT; BETA;

D O I：

10.1016/j.vaccine.2024.05.028

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The emergence and ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for rapid vaccine development platforms that can be updated to counteract emerging variants of currently circulating and future emerging coronaviruses. Here we report the development of a "train model" subunit vaccine platform that contains a SARS-CoV-2 Wuhan S1 protein (the "engine") linked to a series of flexible receptor binding domains (RBDs; the "cars") derived from SARS-CoV-2 variants of concern (VOCs). We demonstrate that these linked subunit vaccines when combined with Sepivac SWETM, a squalene in water emulsion (SWE) adjuvant, are immunogenic in Syrian hamsters and subsequently provide protection from infection with SARS-CoV-2 VOCs Omicron (BA.1), Delta, and Beta. Importantly, the bivalent and trivalent vaccine candidates offered protection against some heterologous SARS-CoV-2 VOCs that were not included in the vaccine design, demonstrating the potential for broad protection against a range of different VOCs. Furthermore, these formulated vaccine candidates were stable at 2-8 degrees C for up to 13 months post-formulation, highlighting their utility in low-resource settings. Indeed, our vaccine platform will enable the development of safe and broadly protective vaccines against emerging betacoronaviruses that pose a significant health risk for humans and agricultural animals.

引用

页数：13